Thieler Law Corp advises investors with losses exceeding $100,000 of the May 6, 2019 lead plaintiff deadline in a class action lawsuit filed against Inogen Inc (NASDAQ: INGN) (“Inogen” or “the Company”). The suit is pending in the U.S. District Court for the Central District of California and investors, who purchased Inogen Inc securities between November 8, 2017 and February 26, 2019, have until May 6, 2019 to move for lead plaintiff. You do not need to move for lead plaintiff to be a member of the Class.

If you purchased Inogen Inc securities during the Class Period, and have losses over $100,000, you may contact Thieler Law Corp by calling at (619) 377 - 4324 or emailing mail@thielerlaw.com . No class has been certified in this case, and if your losses are less than $100,000 you are still a member of the class.

The complaint alleges that during the Class Period defendants made false and misleading statements and/or allegedly failed to disclose that Inogen had overstated the true size of the total addressable market (''TAM'') for its portable oxygen concentrators and had misstated the basis for its calculation of the TAM; Inogen had falsely attributed its sales growth to the strong sales acumen of its salesforce, when in reality it was due in large part to sales tactics designed to deceive its elderly customer base; the growth in Inogen's domestic business-to-business sales to home medical equipment (''HME&'') providers was inflated, unsustainable and was eroding direct-to-consumer sales; and very little of Inogen's business was actually coming from the more stable Medicare market.

On February 26, 2019, the Company revealed its fourth quarter and fiscal year 2018 financial and operating results and held a conference call with investors and analysts to discuss its business metrics and financial prospects. During the call, the Company's Chief Executive Officer backtracked on Inogen's prior total addressable market (“TAM”) estimate of 2.5 to 3 million patients, and blamed Inogen's poor "domestic business-to-business sales" on "order activity [that] slow[ed] from one national home care provider in the fourth quarter of 2018." Inogen also reported that its non-GAAP EBITDA for the quarter was $10.5 million, 9.5% lower than in fiscal 2017, and significantly reduced its previously provided 2019 net income guidance, citing in large part the decline in its own stock price.

Following this news, NASDAQ: INGN fell $33.77 per share, or more than 24%, to close at $106.28 per share on February 27, 2019.

If you were negatively impacted by your investment in Inogen Inc securities between November 8, 2017 and February 26, 2019 and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, please contact us for your no-cost evaluation.

Thieler Law Corp purchases advertisements on search engines, social media sites and other websites. If you send us information, note that does not create an attorney-client relationship with the firm. Materials are provided for informational purposes only and do not constitute legal advice. We are only licensed to practice law in Germany. We are neither licensed nor qualified to render advice on US Federal or State law.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/

or

Facsimile: +1 (619) 785 – 3185